---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-031590"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:33:07.061640+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio partners with CGT Catapult to scale CORDStrom manufacturing for commercial readiness

## Summary
- Partnership with Cell and Gene Therapy Catapult aims to establish large-scale commercial manufacturing for cell therapy platforms.
- Initial focus on scaling CORDStrom for RDEB; Phase 2 trial showed reduced pain/itch and improved skin integrity.
- INmune estimates 4,000 children with intermediate-to-severe RDEB in US/UK/EU could benefit from CORDStrom.
- Following CORDStrom, INmune plans to transition INKmune production to same facility for solid tumor trials.
- Manufacturing will leverage CGT Catapult's Stevenage Innovation Centre and existing Royal Free Hospital base.

## SEC filing metadata
- accession: 0001213900-25-031590
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/0001213900-25-031590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-031590
- JSON: https://secwatch.observer/filing/0001213900-25-031590.json
- Plain text: https://secwatch.observer/filing/0001213900-25-031590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.